Uric Acid: Is It Time to Come in From the Cold?

“Syndrome.” Merriam-Webster.com Dictionary, Merriam-Webster. Accessed at https://www.merriam-webster.com/dictionary/syndrome on March 10, 2022.

Han AL , Lee HK . Association of the metabolic dysfunction-associated fatty liver disease with serum uric acid-to-creatinine ratio. Metab Syndr Relat Disord, 2021; 19:70–75.

Fang J , Alderman MH . Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA, 2000; 283:2404–2410.

Niskanen LK , Laaksonen DE , Nyyssönen K , et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med, 2004; 164:1546–1551.

Choi HK , Curhan G . Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 2007; 116:894–900.

Kuo CF , See LC , Yu KH , et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford), 2013; 52:127–134.

Kivity S , Kopel E , Maor E , et al. Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol, 2013; 111:1146–1151.

Johnson RJ , Segal MS , Srinivas T , et al. Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link?. J Am Soc Nephrol, 2005; 16:1909–1919.

Baker JF , Krishnan E , Chen L , et al. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?. Am J Med, 2005; 118:816–826.

Culleton BF , Larson MG , Kannel WB , et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med, 1999; 131:7–13.

Wannamethee SG , Shaper AG , Whincup PH . Serum urate and the risk of major coronary heart disease events. Heart, 1997; 78:147–153.

Wheeler JG , Juzwishin KD , Eiriksdottir G , et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis. PLoS Med, 2005; 2:e76.

Feig DI , Kang DH , Johnson RJ . Uric acid and cardiovascular risk. N Engl J Med, 2008; 359:1811–1821.

Krishnan E , Sokolove J . Uric acid in heart disease: A new C-reactive protein?. Curr Opin Rheumatol, 2011; 23:174–177.

Modan M , Halkin H , Karasik A , et al. Elevated serum uric acid—A facet of hyperinsulinaemia. Diabetologia, 1987; 30:713–718.

Kleber ME , Delgado G , Grammer TB , et al. Uric acid and cardiovascular events: A Mendelian Randomization Study. J Am Soc Nephrol, 2015; 26:2831–2838.

Kei A , Koutsouka F , Makri A , et al. Uric acid and cardiovascular risk: What genes can say. Int J Clin Pract, 2018; 72:e13048.

Bailey CJ . Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab, 2019; 21:1291–1298.

Goicoechea M , de Vinuesa SG , Verdalles U , et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol, 2010; 5:1388–1393.

Kim SC , Neogi T , Kang EH , et al. Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J Am Coll Cardiol, 2018; 71:994–1004.

Vedder D , Walrabenstein W , Heslinga M , et al. Dietary interventions for gout and effect on cardiovascular risk factors: A systematic review. Nutrients, 2019; 11:2955.

Sanchez-Lozada LG , Rodriguez-Iturbe B , Kelley EE , et al. Uric acid and hypertension: An update with recommendations. Am J Hypertens, 2020; 33:583–594.

Maloberti A , Giannattasio C , Bombelli M , et al.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and Risk of Cardiovascular Outcomes: The experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev, 2020; 27:121–128.

Bedogni G , Miglioli L , Masutti F , et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005; 42:44–52.

Sakurai Y , Kubota N , Yamauchi T , et al. Role of insulin resistance in MAFLD. Int J Mol Sci, 2021; 22:4156.

Adams LA , Lymp JF , St Sauver J , et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology, 2005; 129:113–121.

Marchesini G , Brizi M , Bianchi G , et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes, 2001; 50:1844–1850.

Eslam M , Sanyal AJ , George J , et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020; 158:1999–2014.e1.

Castera L , Friedrich-Rust M , Loomba R . Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019; 156:1264–1281.e4.